Argireline vs Retatrutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Argireline
Argireline (Acetyl Hexapeptide-3) is a widely-used cosmetic peptide that reduces wrinkle depth by inhibiting neurotransmitter release. One of the first 'Botox-like' peptides developed for topical use.
Full details →Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Side-by-Side Comparison
| Aspect | Argireline | Retatrutide |
|---|---|---|
| Mechanism | Inhibits the formation of the SNARE complex required for neurotransmitter release, reducing the intensity of muscle contractions that cause expression lines. | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. |
| Typical Dosage | Topical: 5-10% concentration in serums, applied twice daily. Higher concentrations used in professional treatments. | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. |
| Administration | Topical application to clean skin. Most effective on expression lines (forehead, crow's feet). Consistent use required for visible results. | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. |
| Side Effects | Generally very well-tolerated. Occasional mild irritation or dryness. No systemic absorption at cosmetic doses. | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. |
| Best For |